Cambridge Cognition describes itself as a neuroscience technology company. It provides digital cognitive assessments under the CANTAB and Winterlight brands. Most of its income comes from pharmaceutical and biotechnology companies that use its tools to measure cognition in clinical studies. The interim results said …
TheBusinesswas built around the Parsortix system, a technology designed to capture and harvest circulating tumour cells from blood samples, an approach often called liquid biopsy. Such cells can be analysed by researchers and pharmaceutical companies to study cancer without invasive tissue biopsies. The group …
Bioventix develops and supplies sheep monoclonal antibodies to diagnostic companies, which use them in automated blood-testing machines in hospitals and laboratories. It earnsRevenuefrom antibody sales and from royalties on the tests that use them. Its established products include antibodies for vitamin D and a …
Oxford BioDynamics Plc (LSE:OBD), the Oxford-based biotechnology company developing precision clinical diagnostics, rose 5.71% on 7 October 2026. The AIM-quoted company, a member of the FTSE AIM All-Share Index, uses its proprietary EpiSwitch 3D genomic platform to create blood tests and analytical tools for …
Verici Dx Plc (LSE:VRCI), the developer of advanced clinical diagnostics for organ transplantation, rose 7.14% on 7 October 2026. The AIM-quoted company, part of the FTSE AIM All-Share Index, has seen renewed interest as its flagship Tutivia blood test gains traction in US kidney …
Creo Medical Group Plc (LSE:CREO), the medical device company focused on minimally invasive surgical endoscopy for pre-cancer and cancer patients, rose 2.94% on 7 October 2026. The company had said it expected the sale of its remaining 49% interest in Creo Medical SL to …
hVIVO plc (LSE:HVO), the world leader in human challengeClinical Trialsand a full-service early-phase clinical development partner, rose 6.09% on 7 October 2026. The AIM-quoted company, a constituent of the FTSE AIM All-Share Index, has been working through a difficult period for the contract research …
The shares fell about 21% to around 0.71p on the day of that update. They opened at about 0.65p on 1 October, close to a 52-week low of 0.64p, and Wednesday's drop pushed them to fresh lows. The company'sMarket Valuenow stands at only around …
Arecor uses its proprietary formulation technology platform, known as Arestat, to develop improved versions of existing therapeutic products. The aim is to make medicines more stable, faster acting or easier to use, for example by enabling ready-to-use liquid formats or more concentrated doses. Its …
Avacta develops targeted cancer therapies built on its pre|CISION platform. The technology is designed to keep potent chemotherapy payloads inactive until they reach the tumour, where they are released by an enzyme found at high levels in the tumour microenvironment. The aim is to …